No evidence of disease activity (NEDA-3) and disability improvement after alemtuzumab treatment for multiple sclerosis: a 36-month real-world studyLuca Prosperini, Giancarlo Di Battista, Luigina Musu et al.|Journal of Neurology|2018Cited by 54
Effects of THC/CBD oromucosal spray on spasticity-related symptoms in people with multiple sclerosis: results from a retrospective multicenter studyMario Zappia, Francesco Patti, Clara Grazia Chisari et al.|Neurological Sciences|2020Cited by 26
COVID-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patientsAlvino Bisecco, Daniela Cargnelutti, Federica Matrone et al.|Journal of Neurology|2023Cited by 12
Nabiximols discontinuation rate in a large population of patients with multiple sclerosis: a 18-month multicentre studyClara Grazia Chisari, Francesco Patti, Claudio Solaro et al.|Journal of Neurology Neurosurgery & Psychiatry|2020Cited by 9